NYSE · LLY
Eli Lilly and Company
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
Loading market information…
ASX · IMR.AX · AUD
Stock price, earnings
Quote as of Oct 30, 2026, 05:10 AM UTC. Cached market data; not a live quote.
One-year closing-price history · AUD. Historical prices are not a forecast.
Imricor Medical Systems, Inc.’s quoted price sits in the lower half of its reported 52-week range, 40.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Imricor Medical Systems, Inc.’s next earnings report is currently expected on Dec 2, 2026, with estimated earnings per share of -A$0.03. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Imricor Medical Systems, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Imricor Medical Systems, Inc., a medical device company, designs, manufactures, sells, and distributes magnetic resonance imaging (MRI) compatible products for cardiac catheter ablation procedures in the United States, Europe, and the Middle East. The company’s products include Vision-MR Ablation Catheter 2.0, a MR-compatible cardiac ablation catheter; Vision-MR Diagnostic Catheter, a MR-compatible diagnostic catheter; NorthStar mapping system, a real-time, high-resolution soft tissue imaging of MRI to guide and visualize procedures with exceptional clarity; and Advantage-MR EP Recorder / Stimulator. It also offers Vision-MR Dispersive Electrode to minimize eddy currents induced on the device’s conductive pads during mr scanning. Imricor Medical Systems, Inc. was incorporated in 2006 and is headquartered in Burnsville, Minnesota.
Latest available per-share figures in AUD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:34 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2023 | Jan 31, 2024 | -A$0.09 | A$298.81K-94.86% vs estimate |
|---|
| Q4 2022 | Feb 22, 2023 | -A$0.07 | A$406.99K-96.3% vs estimate |
|---|
| Q2 2022 | Aug 29, 2022 | -A$0.10 | A$779.62K-89.85% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
$275.20+$4.16 (+1.53%)
Johnson & Johnson’s quoted price sits in the upper half of its reported 52-week range, 2.09% below the high.
$290.97+$4.98 (+1.74%)
AbbVie Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.55% below the high.
$410.91+$3.81 (+0.94%)
UnitedHealth Group Incorporated’s quoted price sits in the upper half of its reported 52-week range, 10.99% below the high.
$146.33+$5.40 (+3.83%)
Merck & Co., Inc.’s quoted price sits in the upper half of its reported 52-week range, 6.75% below the high.
$709.18+$5.03 (+0.71%)
Thermo Fisher Scientific Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.38% below the high.
$460.73+$8.90 (+1.97%)
Amgen Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.61% below the high.
$165.61+$6.41 (+4.03%)
Gilead Sciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.05% below the high.
